{"entity":{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","aka":[],"tldr":"A growth-factor receptor that is mutated or fused in a sizeable minority of bladder cancers. Erdafitinib blocks it and is the first targeted drug approved for urothelial cancer selected by a genomic test.","summary":"FGFR3 activating mutations and FGFR3::TACC3 fusions drive a subset of urothelial carcinomas, especially the luminal-papillary type, and are also common in non-invasive bladder tumours. Erdafitinib, a pan-FGFR inhibitor, received accelerated US approval in 2019 for FGFR3- or FGFR2-altered advanced urothelial cancer and full approval in 2024 after the THOR trial showed a survival benefit over chemotherapy in patients previously treated with a checkpoint inhibitor. Hyperphosphataemia, from FGFR1 blockade in the kidney, and eye toxicity are the class effects. FGFR3-altered tumours tend to be immunologically cold, which shapes the debate about sequencing targeted therapy and immunotherapy.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_3","links":[{"label":"UniProt P22607: FGFR3","url":"https://www.uniprot.org/uniprotkb/P22607/entry"}],"tags":[],"related":["fgfr2","fgfr3-alteration"],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["erdafitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["thor"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"FGFR3","role":[],"sources":[],"specificity":"tumour-specific","distribution":"one-type","specificityNote":"Tumour-specific alteration: 1 of 1 label readouts filed under it measure a sequence variant (FGFR3 alteration (mutation or fusion)) absent from normal cells. HPA FGFR3: RNA tissue enhanced (brain 149 nTPM, esophagus 127 nTPM, skin 1 257 nTPM); high antibody staining in 3 normal tissues; highest cancer staining testis cancer (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer); Open Targets associates it with 14 specific cancer types at or above 0.5 (urinary bladder carcinoma, urinary bladder cancer, nevus, epidermal, cervical cancer, colorectal cancer, renal cell carcinoma and more); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 3 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"FGFR3 alteration (mutation or fusion) label threshold","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee","note":"Susceptible FGFR3 genetic alteration"},{"label":"Human Protein Atlas FGFR3 tissue","url":"https://www.proteinatlas.org/ENSG00000068078-FGFR3/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000068078 associations","url":"https://platform.opentargets.org/target/ENSG00000068078/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3690","ensembl":"ENSG00000068078","uniprot":"P22607","entrez":"2261","firstDescribed":1990,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Partanen et al, Proc. Natl. Acad. Sci. U.S.A, 1990, \"Putative tyrosine kinases expressed in K-562 human leukemia cells\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2247464/","biology":"Receptor tyrosine kinase for fibroblast growth factors; activating point mutations (S249C, Y373C) and TACC3 fusions in urothelial carcinoma.","whereFound":["Urothelial carcinoma, most often luminal-papillary and non-invasive tumours","Multiple myeloma with t(4;14)"],"targetClass":"kinase","prevalence":[{"cancerId":"urothelial","pct":"15-20","measure":"FGFR3 mutation or FGFR2/3 fusion in advanced urothelial carcinoma","source":"https://doi.org/10.1056/NEJMoa1817323","note":"The BLC2001 trial of erdafitinib enrolled patients with these alterations, which its report describes as present in roughly a fifth of advanced urothelial carcinomas."}]},"route":"/targets/fgfr3-receptor/","neighbours":{"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"biomarker":[{"id":"fgfr3-alteration","kind":"biomarker","name":"FGFR3 alteration (mutation or fusion)","route":"/biomarkers/fgfr3-alteration/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"drug":[{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/"}],"trial":[{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/"}]}}